Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 9/2023

10.07.2023 | Lipid Abnormalities and Cardiovascular Prevention (ED Michos, Section Editor)

Pleiotropy of PCSK9: Functions in Extrahepatic Tissues

verfasst von: Yusuf Ziya Şener, Lale Tokgözoğlu

Erschienen in: Current Cardiology Reports | Ausgabe 9/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a central role in the metabolism of LDL receptors and mainly acts in the liver. However, there are accumulating data that PCSK9 involves in several functions in different organs beyond the liver. Herein we aimed to summarize the effects of PCSK9 in tissues other than the liver.

Recent Findings

PCSK9 has crucial roles in heart, brain and kidney in addition to the cholesterol metabolism. Targeting PCSK9 for the treatment of hypercholesterolemia is effective in the prevention from cardiovascular diseases and PCSK9 inhibitors are getting to be administered in more cases. Therefore understanding the effects of PCSK9 in other tissues gained importance in the use of PCSK9 inhibitors era.

Summary

PCSK9 participates in cardiac, renal, and neurologic functions however, current literature reveals that use of PSCSK9 inhibitors have beneficial or neutral effects on these organs. Inhibition of PCSK9 is assigned to be associated with new onset diabetes in experimental studies whereas real world data with PCSK9 inhibitors established no relationship between PCSK9 inhibitors and new onset diabetes. PCSK9 might be used as a target for the treatment of nephrotic syndrome and heart failure in the future.
Literatur
1.
Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227–337.PubMedCrossRef
2.
3.
Ferri N. Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases. Scientifica (Cairo). 2012;2012: 927352.PubMed
4.
Poirier S, Mayer G, Benjannet S, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem. 2008;283:2363–72.PubMedCrossRef
5.
Chiang LW, Grenier JM, Ettwiller L, et al. An orchestrated gene expression component of neuronal programmed cell death revealed by cDNA array analysis. Proc Natl Acad Sci U S A. 2001;98:2814–9.PubMedPubMedCentralCrossRef
6.
O’Connell EM, Lohoff FW. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders. Front Neurosci. 2020;14:609.PubMedPubMedCentralCrossRef
7.
Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003;100:928–33.PubMedPubMedCentralCrossRef
8.
Poirier S, Prat A, Marcinkiewicz E, et al. Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system. J Neurochem. 2006;98:838–50.PubMedCrossRef
9.
An D, Wei X, Li H, et al. Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics. Sci Rep. 2015;5:17559.PubMedPubMedCentralCrossRef
10.
Zimetti F, Caffarra P, Ronda N, et al. Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer’s Disease. J Alzheimers Dis. 2017;55:315–20.PubMedCrossRef
11.
Picard C, Poirier A, Bélanger S, Labonté A, Auld D, Poirier J. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer’s disease: A genetic and proteomic multi-cohort study. PLoS ONE. 2019;14: e0220254.PubMedPubMedCentralCrossRef
12.
Ma SL, Ng HK, Baum L, et al. Low-density lipoprotein receptor-related protein 8 (apolipoprotein E receptor 2) gene polymorphisms in Alzheimer’s disease. Neurosci Lett. 2002;332:216–8.PubMedCrossRef
13.
Rousselet E, Marcinkiewicz J, Kriz J, et al. PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke. J Lipid Res. 2011;52:1383–91.PubMedPubMedCentralCrossRef
14.
•• Rohrbach S, Li L, Novoyatleva T, et al. Impact of PCSK9 on CTRP9-Induced Metabolic Effects in Adult Rat Cardiomyocytes. Front Physiol. 2021;12:593862. Findings of this study suggests that PCSK9 regulates myocardial energy metabolism and exogenous PCSK9 inhibits the uptake of free fatty acids from cardiomyocytes which may play a significant role in heart failure pathogenesis.
15.
Jonas MC, Costantini C, Puglielli L. PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1. EMBO Rep. 2008;9:916–22.PubMedPubMedCentralCrossRef
16.
Benn M, Nordestgaard BG, Frikke-Schmidt R, Tybjærg-Hansen A. Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study. BMJ. 2017;357: j1648.PubMedPubMedCentralCrossRef
17.
Han DF, Ma JH, Hao CG, Tuerhong T, Du L, Zhang XN. Association and differences in genetic polymorphisms in PCSK9 gene in subjects with lacunar infarction in the Han and Uygur populations of Xinjiang Uygur Autonomous Region of China. Neural Regen Res. 2017;12:1315–21.PubMedPubMedCentralCrossRef
18.
Chen YQ, Troutt JS, Konrad RJ. PCSK9 is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day. Lipids. 2014;49:445–55.PubMedCrossRef
19.
Rosoff DB, Bell AS, Jung J, Wagner J, Mavromatis LA, Lohoff FW. Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function. J Am Coll Cardiol. 2022;80:653–62.PubMedCrossRef
20.
Giugliano RP, Mach F, Zavitz K, et al. Cognitive Function in a Randomized Trial of Evolocumab. N Engl J Med. 2017;377:633–43.PubMedCrossRef
21.
Janik MJ, Urbach DV, van Nieuwenhuizen E, et al. Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: A prospective, randomized, placebo-controlled study. Atherosclerosis. 2021;331:20–7.PubMedCrossRef
22.
Gencer B, Mach F, Guo J, et al. Cognition After Lowering LDL-Cholesterol With Evolocumab. J Am Coll Cardiol. 2020;75:2283–93.PubMedCrossRef
23.
O’Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. Circulation. 2022;146:1109–19.PubMedCrossRef
24.
25.
Akhmedov A, Rozenberg I, Paneni F, et al. Endothelial overexpression of LOX-1 increases plaque formation and promotes atherosclerosis in vivo. Eur Heart J. 2014;35:2839–48.PubMedCrossRef
26.
Ding Z, Wang X, Liu S, et al. PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy. Cardiovasc Res. 2018;114:1738–51.PubMedCrossRef
27.
Palee S, McSweeney CM, Maneechote C, et al. PCSK9 inhibitor improves cardiac function and reduces infarct size in rats with ischaemia/reperfusion injury: Benefits beyond lipid-lowering effects. J Cell Mol Med. 2019;23:7310–9.PubMedPubMedCentralCrossRef
28.
Liu LS, Bai XQ, Gao Y, et al. PCSK9 Promotes oxLDL-Induced PC12 Cell Apoptosis Through the Bcl-2/Bax-Caspase 9/3 Signaling Pathway. J Alzheimers Dis. 2017;57:723–34.PubMedCrossRef
29.
Trankle CR, Wohlford G, Buckley LF, et al. Alirocumab in Acute Myocardial Infarction: Results From the Virginia Commonwealth University Alirocumab Response Trial (VCU-AlirocRT). J Cardiovasc Pharmacol. 2019;74:266–9.PubMedPubMedCentralCrossRef
30.
Wang X, Li X, Liu S, et al. PCSK9 regulates pyroptosis via mtDNA damage in chronic myocardial ischemia. Basic Res Cardiol. 2020;115:66.PubMedCrossRef
31.
Chen X, Xu S, Zhao C, Liu B. Role of TLR4/NADPH oxidase 4 pathway in promoting cell death through autophagy and ferroptosis during heart failure. Biochem Biophys Res Commun. 2019;516:37–43.PubMedCrossRef
32.
Tang ZH, Peng J, Ren Z, et al. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway. Atherosclerosis. 2017;262:113–22.PubMedCrossRef
33.
Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 2002;14:381–95.PubMedCrossRef
34.
Xu Q, Zhao YM, He NQ, et al. PCSK9: A emerging participant in heart failure. Biomed Pharmacother. 2023;158: 114106.PubMedCrossRef
35.
Andreadou I, Tsoumani M, Vilahur G, et al. PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation. Front Physiol. 2020;11: 602497.PubMedPubMedCentralCrossRef
36.
Zeng C, Duan F, Hu J, et al. NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy. Redox Biol. 2020;34: 101523.PubMedPubMedCentralCrossRef
37.
Wei H, Bu R, Yang Q, et al. Exendin-4 Protects against Hyperglycemia-Induced Cardiomyocyte Pyroptosis via the AMPK-TXNIP Pathway. J Diabetes Res. 2019;2019:8905917.PubMedPubMedCentralCrossRef
38.
White HD, Schwartz GG, Szarek M, et al. Alirocumab after acute coronary syndrome in patients with a history of heart failure. Eur Heart J. 2022;43:1554–65.PubMedCrossRef
39.
•• Ramin-Mangata S, Thedrez A, Nativel B, et al. Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function. Atherosclerosis. 2021;326:47–55. Findings from this study reveals that despite PCSK9 regulates LDLR density in beta cells, PSCK9 inhibition does not affect insulin secretion.
40.
Carugo S, Sirtori CR, Corsini A, Tokgozoglu L, Ruscica M. PCSK9 Inhibition and Risk of Diabetes: Should We Worry? Curr Atheroscler Rep. 2022;24:995–1004.PubMedPubMedCentralCrossRef
41.
Da Dalt L, Ruscica M, Bonacina F, et al. PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor. Eur Heart J. 2019;40:357–68.PubMedCrossRef
42.
Schmidt AF, Holmes MV, Preiss D, et al. Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9. BMC Cardiovasc Disord. 2019;19:240.PubMedPubMedCentralCrossRef
43.
Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. N Engl J Med. 2016;375:2144–53.PubMedCrossRef
44.
Lotta LA, Sharp SJ, Burgess S, et al. Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis. JAMA. 2016;316:1383–91.PubMedPubMedCentralCrossRef
45.
Cupido AJ, Reeskamp LF, Hingorani AD, et al. Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease: A Factorial Mendelian Randomization Study. JAMA Cardiol. 2022;7:955–64.PubMedPubMedCentralCrossRef
46.
Soremekun O, Karhunen V, He Y, et al. Lipid traits and type 2 diabetes risk in African ancestry individuals: A Mendelian Randomization study. EBioMedicine. 2022;78: 103953.PubMedPubMedCentralCrossRef
47.
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376:1713–22.PubMedCrossRef
48.
Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379:2097–107.PubMedCrossRef
49.
Haas ME, Levenson AE, Sun X, et al. The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia. Circulation. 2016;134:61–72.PubMedPubMedCentralCrossRef
50.
Jin K, Park BS, Kim YW, Vaziri ND. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study. Am J Kidney Dis. 2014;63:584–9.PubMedCrossRef
51.
Kwakernaak AJ, Lambert G, Slagman MC, et al. Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment. Atherosclerosis. 2013;226:459–65.PubMedCrossRef
52.
Okamura DM, Pennathur S, Pasichnyk K, et al. CD36 regulates oxidative stress and inflammation in hypercholesterolemic CKD. J Am Soc Nephrol. 2009;20:495–505.PubMedPubMedCentralCrossRef
53.
Byun JH, Lebeau PF, Platko K, et al. Inhibitory Antibodies against PCSK9 Reduce Surface CD36 and Mitigate Diet-Induced Renal Lipotoxicity. Kidney360. 2022;3:1394–1410.
54.
Berger JM, Vaillant N, Le May C, et al. PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension. Atherosclerosis. 2015;239:252–9.PubMedCrossRef
55.
Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264–72.PubMedCrossRef
56.
Cesaro A, Bianconi V, Gragnano F, et al. Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition. Biofactors. 2020;46:367–80.
57.
Igweonu-Nwakile EO, Ali S, Paul S, et al. A Systematic Review on the Safety and Efficacy of PCSK9 Inhibitors in Lowering Cardiovascular Risks in Patients With Chronic Kidney Disease. Cureus. 2022;14: e29140.PubMedPubMedCentral
58.
Le May C, Kourimate S, Langhi C, et al. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol. 2009;29:684–90.PubMedCrossRef
59.
Leblond F, Seidah NG, Précourt LP, Delvin E, Dominguez M, Levy E. Regulation of the proprotein convertase subtilisin/kexin type 9 in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2009;296:G805–15.PubMedCrossRef
60.
Langhi C, Le May C, Kourimate S, et al. Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. FEBS Lett. 2008;582:949–55.PubMedCrossRef
61.
Veilleux A, Grenier E, Marceau P, Carpentier AC, Richard D, Levy E. Intestinal lipid handling: evidence and implication of insulin signaling abnormalities in human obese subjects. Arterioscler Thromb Vasc Biol. 2014;34:644–53.PubMedCrossRef
62.
Levy E, Lalonde G, Delvin E, et al. Intestinal and hepatic cholesterol carriers in diabetic Psammomys obesus. Endocrinology. 2010;151:958–70.PubMedCrossRef
63.
Cariou B, Si-Tayeb K, Le May C. Role of PCSK9 beyond liver involvement. Curr Opin Lipidol. 2015;26:155–61.PubMedCrossRef
64.
Le May C, Berger JM, Lespine A, et al. Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1. Arterioscler Thromb Vasc Biol. 2013;33:1484–93.PubMedCrossRef
65.
Ding Z, Liu S, Wang X, et al. Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta. Antioxid Redox Signal. 2015;22:760–71.PubMedPubMedCentralCrossRef
66.
Ferri N, Tibolla G, Pirillo A, et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis. 2012;220:381–6.PubMedCrossRef
67.
Kühnast S, van der Hoorn JW, Pieterman EJ, et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res. 2014;55:2103–12.PubMedPubMedCentralCrossRef
Metadaten
Titel
Pleiotropy of PCSK9: Functions in Extrahepatic Tissues
verfasst von
Yusuf Ziya Şener
Lale Tokgözoğlu
Publikationsdatum
10.07.2023
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 9/2023
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-023-01918-2

Weitere Artikel der Ausgabe 9/2023

Current Cardiology Reports 9/2023 Zur Ausgabe

Pericardial Disease (AL Klein and CL Jellis, Section Editors)

Pericardial Effusion and Cardiac Tamponade Pathophysiology and New Approaches to Treatment

Pericardial Disease (AL Klein and CL Jellis, Section Editors)

Paradigm Shift in Diagnosis and Targeted Therapy in Recurrent Pericarditis

Women and Cardiovascular Health (N Goldberg and S Lewis, Section Editors)

Sex Differences in Atrial Fibrillation

Invasive Electrophysiology and Pacing (EK Heist, Section Editor)

COVID-19 Vaccination and Cardiac Arrhythmias: A Review

Women and Cardiovascular Health (N Goldberg and S Lewis, Section Editors)

Addressing Cardiovascular Risk Across the Arc of a Woman’s Life: Sex-Specific Prevention and Treatment

Psychological Aspects of Cardiovascular Diseases (IM Kronish, Section Editor)

Impact of Neighborhood on Cardiovascular Health: A Contemporary Narrative Review

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen